30 metastatic non-small-cell lung cancer patients
Cytopathological analysis identified CCC in 28 patients (93,3%)
By CK+/CD45- IF, epithelial CTC were detected in 17 patients (56,7%)
Median progression-free survival (PFS) was significantly shorter in patients with >3 PD-1(+) CTCs at baseline compared with those with <3 PD-1(+) CTCs (p = 0.022) as well as in patients with >1 Giemsa-positive tumor cells (p = 0.025).
106 lung adenocarcinoma patients (stages III-IV)
Cytopathological analysis identified CCC in 80 patients (75%)
93% concordance of PD-L1 expression between tissue and CTCs (Sensitivity=55%; Specificity=100%)